Search This Blog

Thursday, May 7, 2026

Akebia Q1 loss $0.03 per share on $53.5M revenue misses estimates for $0.01 loss on $56.5M revenue

 

Akebia Therapeutics Q1 loss $0.03 per share on $53.5M revenue misses estimates for $0.01 loss on $56.5M revenue

  • Akebia reported Q1 2026 net loss totaling $9.1 million, compared with revenue of $53.5 million.
  • Vafseo net product revenue rose to $15.8 million in Q1 2026.
  • Company said $162.6 million cash should fund operations for at least two years while advancing kidney disease trials.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)